http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2011522830-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0043 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-16 |
| filingDate | 2009-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2011-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2011522830-A |
| titleOfInvention | Insulin preparation for insulin |
| abstract | The present invention provides a method for achieving a therapeutically effective plasma insulin concentration by administering an insulin pharmaceutical formulation in the same nostril at least two consecutive doses. is there. When the second dose is administered to the same nostril, the plasma insulin concentration is significantly higher than when administered sequentially to two different nostrils. The first dose of insulin is not limited to any particular physiological mechanism, but is believed to function as a fill dose to the nasal mucosa. This fill dose is necessary to achieve the plasma insulin concentration found in subsequent dose administration. The Cmax of plasma insulin achieved by the methods and formulations of the invention is at least about 70 μU / ml when plasma insulin is measured in a period of 0 minutes to about 45 minutes after administration of the second dose. It may be. The AUC achieved may be at least 1800 μU / (ml × min). [Selection figure] None |
| priorityDate | 2008-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 356.